Is Guardant Health, Inc. (GH) a Buy, Sell, or Hold?

Enter your email address below for free access to our Guardant Health, Inc. (GH) research center and poll results.

NASDAQ : GH

Guardant Health, Inc.

$155.87 USD

$0.87 (0.56%)

Volume: 2M
Average Volume: 2.68M
Market Capitalization: $20.67B
P/E Ratio: -45.98
Dividend Yield: 0.00%
Price Target: $175.00

Year High: $174.08
Year Low: $40.35
Day High: —
Day Low: —
Payout Ratio: $0.00
Current Ratio: $4.68

Price Target and Rating

Average Stock Price Forecast	$175.00
High Stock Price Forecast	$205.00
Low Stock Price Forecast	$115.00
Forecast Upside/Downside	-10.93%
Consensus Rating	Sell
Rating Score(0-5)	2
Research Coverage	30 Analysts

Profitability

EPS (Most Recent Fiscal Year)	-$3.32
Trailing P/E Ratio	-45.98
PEG Ratio	133.79
P/E Growth	133.79
Net Income	-$416.28M
Net Margin	-40.10%
Pretax Margin	-40.21%
Return on Equity	184.27%
Return on Assets	-22.62%

Financials Score

AltmanZ Score	4.14
Piotroski Score	4.00
Working Capital	1.08B
Total Assets	1.92B
Ebit	-429.92M
Market Cap	20.67B
Total Liabilities	2.1B

Poll Results

About Guardant Health, Inc. (NASDAQ:GH) Stock

Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal can ... cer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.

Artisan Mid Cap Fund Q2 2026 Performance Review

2026-07-15 13:56:00

Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple positions rising more than 100% during the period. During the quarter, we initiated new positions in Entegris, Modine Manufacturing and C.H. Robinson Worldwide.

ISCG vs. RZG: Which Small-Cap Growth ETF Is the Better Buy for Investors?

2026-07-13 06:45:23

ISCG offers lower fees and broader diversification, while RZG's portfolio strategy has outperformed over the past five years

Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026

2026-07-09 16:05:00

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will.

The Surprising Reason Guardant Health, A Top 3% Stock, Soared To A Five-Year High

2026-07-09 13:05:03

Guardant Health stock jumped Thursday after key competitor, Freenome, unveiled study results for its colon cancer blood test.

Which Small Cap ETF Is the Better Buy in 2026? iShares and JPMorgan Have Compelling Offerings

2026-07-07 13:18:54

ISCB offers ultra-low costs and 1,500+ holdings for diversification, while BBSC concentrates on fewer names with higher recent returns.

UnitedHealth Group Now Covers Guardant Health's Shield Blood Test for Colorectal Cancer Screening

2026-07-01 14:50:00

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) is now covered for eligible UnitedHealth Group (UHG) members1, making it the first major commercial insurer to provide coverage for adults 45 or older amid rising CRC rates for adults under 652 and mortality for younger adults as the leading cause of cancer death for those under 50.3 Shield is the first and onl.

State Street SPDR Small Cap ETF Outpaces iShares on Returns

2026-06-30 08:15:01

Explore how portfolio size and sector exposure differ between these two small-cap ETFs, each offering unique advantages for investors.

Living Longer Is Big Business. These Stocks Will Benefit.

2026-06-18 14:14:00

TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.

Frequently Asked Questions

What is the current Guardant Health, Inc. (GH) stock price?: Guardant Health, Inc.(NASDAQ:GH) stock price is $155.87 in the last trading session. During the trading session, GH stock reached the peak price of $174.08 while $40.35 was the lowest point it dropped to. The percentage change in GH stock occurred in the recent session was 0.56% while the dollar amount for the price change in GH stock was $0.87.
GH's industry and sector of operation?: The NASDAQ listed GH is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
Who are the executives of GH?: Andy Ament | Senior Vice President of Operations
John G. Saia | Chief Legal Officer & Corporate Secretary
Zarak Khurshid | Vice President of Investor Relations
Gulshan Shaver | Senior Vice President of Legal Affairs & Chief Compliance Officer
Kumud Kalia | Chief Information Officer
How many employees does GH have?: Number of GH employees currently stands at 2506. GH operates from 3100 Hanover Street, Palo Alto, CA 94063, US.

Link for GH official website?: Official Website of GH is: https://guardanthealth.com
How do I contact GH?: GH could be contacted at phone #855 698 8887 and can also be accessed through its website. GH operates from 3100 Hanover Street, Palo Alto, CA 94063, US.
How many shares of GH are traded daily?: The average number of GH shares traded daily for last 3 months was 2.68M.
What is the market cap of GH currently?: The market value of GH currently stands at $20.67B with its latest stock price at $155.87

Enter your email address below for free access to our Guardant Health, Inc. (GH) research center and poll results.

Guardant Health, Inc.

$155.87 USD

Company Overview

Liquidity Metrics

Sales & Valuation

Profitability

P/E Metrics

Analyst Price Target & Rating

Poll Results